Mirabegron as effective as oxybutynin for ureteral stent symptoms

Data de publicação
Revista da Associacao Medica Brasileira
Citações (Scopus)
Jaworski P.
Mello G.F.
Ferreira G.M.
Oliveira M.H.
De Fraga R.
Título da Revista
ISSN da Revista
Título de Volume
Membros da banca
© 2021 Associacao Medica Brasileira. All rights reserved.OBJECTIVE: Ureteral stents usually cause pain and lower urinary tract discomfort. This study aimed to compare the effect of mirabegron with oxybutynin in relieving ureteral stent-related symptoms over time. METHODS: A prospective, longitudinal, randomized, single-blinded study was conducted. Patients who had a ureteral stent inserted after urolithiasis treatment were classified into two groups and received either oxybutynin 5 mg/day (Group O) or mirabegron 50 mg/ day (Group M). The Ureteral Stent Symptoms Questionnaire (USSQ) was applied on the 3rd, 6th, and 15th postoperative days. Group domain scores were compared, and a mixed linear model was used to better assess score differences. RESULTS: Ureteral Stent Symptoms Questionnaire scores were similar in both groups during all three postoperative days (p>0.05). A longitudinal analysis showed that global quality of life and general health improved over time, independently of the use of any of the medications (p<0.05), while urinary symptoms and body pain scores were lower over time in participants receiving oxybutynin. CONCLUSION: Both mirabegron and oxybutynin are equivalent in relieving ureteral stent symptoms. Moreover, some stent symptoms seem to decrease over time despite the use of medication.
Assuntos Scopus
Acetanilides , Humans , Mandelic Acids , Prospective Studies , Quality of Life , Stents , Surveys and Questionnaires , Thiazoles
DOI (Texto completo)